Analysts Set Omnicell, Inc. (NASDAQ:OMCL) Target Price at $52.00

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) has been assigned a consensus rating of "Hold" from the six analysts that are presently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $52.00.

A number of research analysts have recently issued reports on the company. StockNews.com downgraded Omnicell from a "buy" rating to a "hold" rating in a report on Tuesday, December 10th. Benchmark reissued a "buy" rating and set a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Craig Hallum raised their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Wells Fargo & Company boosted their target price on shares of Omnicell from $30.00 to $41.00 and gave the company an "equal weight" rating in a research note on Monday, October 14th. Finally, Bank of America restated a "neutral" rating and issued a $57.00 price target (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st.

Omnicell Stock Performance

Shares of NASDAQ:OMCL traded down $0.52 during trading on Friday, reaching $44.06. 206,707 shares of the stock traded hands, compared to its average volume of 541,558. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.74. The stock has a market cap of $2.04 billion, a P/E ratio of -112.97, a price-to-earnings-growth ratio of 34.96 and a beta of 0.77. The stock has a 50-day moving average of $45.73 and a two-hundred day moving average of $40.06.

Insider Buying and Selling

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.64% of the stock is owned by insiders.

Institutional Trading of Omnicell

Several institutional investors have recently made changes to their positions in OMCL. Pacer Advisors Inc. grew its holdings in Omnicell by 32.6% during the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company's stock valued at $56,047,000 after buying an additional 508,789 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Omnicell by 0.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company's stock valued at $31,955,000 after acquiring an additional 3,570 shares in the last quarter. Victory Capital Management Inc. increased its holdings in Omnicell by 11,982.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company's stock valued at $50,071,000 after acquiring an additional 1,138,921 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its stake in Omnicell by 27.1% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company's stock worth $49,742,000 after purchasing an additional 243,353 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Omnicell by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company's stock valued at $48,176,000 after purchasing an additional 2,877 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.